Technology: LG Electronics is voluntarily selected microwave ovens

Electrical safety recall

Sydney - /Medianet International-AsiaNet / - LG Electronics is voluntarily recalling selected microwave ovens (manufactured between August 2007 to February 2008) in order to repair a fault which may pose a risk of electric shock to the user.

The products are being recalled because in some cases an internal part of the unit may be loose which may cause an electrical short circuit which will trip the households safety switch. In rare cases this may result in an electric shock to the user in households that do not have a safety switch. This issue does not affect other LG products.

LG Electronics will inspect and, if necessary, repair the unit at no cost to consumers.

Although any risk of electric shock is low, customers are asked to cease use of the product until it has been inspected and repaired.

Customers with the following appliance model numbers and serial number range should contact the Customer Information Line on 0508 643 156 to arrange for an appointment to service the appliance.

Model numbers:
MS-2346VR, MS2347GR
Serial number range:
Serial numbers commencing 708 to 802
Manufactured: August 2007 to February 2008

LG Electronics is liaising with the New Zealand Ministry of Consumer Affairs and New Zealand Ministry of Economic Development in relation to the recall process.

For further information contact the Customer Information Line on 0508 643 156.

LG Electronics would like to apologise for any inconvenience caused to customers.
ENDS

About LG Electronics

LG Electronics (KSE: 06657.KS) is a global leader in providing cutting-edge, convergent electronics, information and communications products designed to meet the diverse needs of fast-changing consumers. With consolidated sales of US$37.7 billion and overseas sales of US$32.6 billion (86% of total sales), LG Electronics employs more than 70,000 employees in 76
subsidiaries located in 39 countries and operates four business units including Mobile Communications, Digital Appliance, Digital Display and Digital Media.

For further information, images or to organise an interview please contact: Nicole Thurston, Burson-Marsteller
Tel: +61 29928 1504 (direct)
Mob: +61 401 677 178
Email: nicole.thurston@bm.com
Fax: +61 2 8805 4201
Bridget Candy, Burson-Marsteller
Tel: +61 2 9928 1549 (direct)
Mob: +61 406 624 284
Email: bridget.candy@bm.com
Fax:+61 2 8805 4201
Distributed on behalf of LG Electronics Australia Pty Ltd,
2 Wonderland Drive, Eastern Creek, NSW, Australia 2766
Phone: +61 2 8805 4000
Source: LG Electronics Australia Pty Ltd

Business: Thomson Reuters publishes Liquent Regulatory Affairs Trends

Philadelphia and London, (ANTARA News/PRNewswire-AsiaNet) - The Scientific business of Thomson Reuters today announced the early findings of its 2008 Liquent Regulatory Affairs Trends Survey.

The survey attracted respondents from across the globe representing small, medium and large pharmaceutical companies and provides a unique insight into emerging and future trends in regulatory product management usage and
adoption.

Now in its sixth year and frequently sourced by pharmaceutical journals and publications across the world, this survey has become the premier benchmark of global regulatory submission trends offering timely insights into how pharmaceutical regulatory professionals use technology today and how they plan to harness technology in the future.

There were 137 Regulatory Affairs professionals working in Life Sciences companies across the globe who participated in this survey. The survey concentrates on four key areas: Technology Usage Trends, including both submission publishing software and other desktop software, Document Management System usage, Regulatory Outsourcing trends, and Regulatory trends including use or future use of the electronic Common Technical Document (eCTD).

The demographic make-up of the respondent population is similar to previous years with almost one third working in large pharmaceutical companies (32 per cent) and more than a third working in small to medium companies (36 per cent).

Another 10 per cent of respondents work for biotechnology companies. There were significantly more respondents from Contract Research Organizations (CROs) in 2008 (10 per cent) than in 2007 (4 per cent). 68 per cent of those surveyed are from the United States and the majority of the remaining respondents are from Europe, with France (4 per cent), Switzerland (4 per cent), the UK (3 per cent) and Germany (3 per cent) the most highly represented.

Survey highlights include:

Technology Usage:

-- Almost all (92 per cent) of the survey respondents make regulatory submissions, a slight increase on 2007 (90 per cent); current use of paper and electronic submissions has remained the same since 2007.

-- Three-quarters (75 per cent) are using submission publishing software, similar to 2007 (67 per cent). Approximately one-third (31 per cent) of those respondents not currently using software are very likely to implement submission publishing software into their process.

-- As in 2007, the SAFE initiative has not yet taken hold in most companies surveyed: only 2 per cent of respondents are currently addressing it.

However, there has been a significant increase in the percentage of companies that are currently using technology to support the FDA Gateway, up to 19 per cent this year, from 9 per cent in 2007.

Regulatory Outsourcing Trends:
-- 30 per cent of respondents do not outsource any of their regulatory operations.
-- Printing (28 per cent) was the regulatory operation outsourced the most by respondents.

Regulatory Trends:
-- Eight in ten (83 per cent) of respondents intend to migrate to the eCTD, with 20 per cent of these reporting they will migrate within the next year.

"This year's survey has once again attracted respondents from across the breadth of the global life sciences industry, with large as well as small to medium sized companies participating," said Jim Nichols, Liquent's Vice President of Product Strategy and Marketing, who launched this worldwide initiative in 2003. "We're particularly excited to see a significant increase in the numbers of Contract Research Organizations (CROs) replying to our survey, further diversifying the population sample."

Full results of the survey are available on request at the following address: http://www.liquent.com/2008survey/

For more information about Liquent regulatory information management services, please go to: http:/www.thomsonreuters.com/products_services/scientific1 liquentinsight

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.

SOURCE Thomson Reuters
CONTACT: Eoin Bedford of Thomson Reuters, Scientific,
+44-207-433-4691, eoin.bedford@thomsonreuters.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080424NYTH069LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web site: http://www.thomsonreuters.com
http://www.liquent.com/2008survey
http://www.thomsonreuters.com/products_services/scientific1
liquentinsight

Health/Medical: BioWa, Medarex announce license of COMPLEGENT Technology

Princeton, N.J., (ANTARA News/PRNewswire-AsiaNet) - BioWa, Inc. and Medarex, Inc. (Nasdaq:MEDX) announced today that they have entered into a license agreement which provides Medarex with the first ever access to BioWa's COMPLEGENT(TM) Technology for enhancing the complement-dependent cytotoxicity (CDC) of select Medarex therapeutic antibodies.

The license grants Medarex non-exclusive rights to research, develop and commercialize therapeutic antibodies based on COMPLEGENT(TM) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payment, license fees, development milestone payments and royalties on products. Other details of the agreement are not disclosed.

"We are very pleased to announce this new partnership with Medarex, who is also our first partner for POTELLIGENT(R) Technology," commented Dr. Masamichi Koike, President and CEO of BioWa. "This collaboration with Medarex greatly helps us explore the potential of COMPLEGENT(TM) Technology for antibody-based therapies."

"We are excited about the possibility of enhancing our antibodies with BioWa's technology platform," said Howard H. Pien, President and CEO of Medarex. "Our partnership grants Medarex the first access to COMPLEGENT(TM) Technology and we look forward to investigating its potential as we continue to advance our pipeline."

About COMPLEGENT(TM) Technology

COMPLEGENT(TM) Technology is a new technology developed by Kyowa Hakko Kogyo Co., Ltd. that enhances one of the major mechanisms of action of an antibody, CDC. With an approach called isotype chimerism, in which portions of IgG3, an antibody's isotype, are introduced into corresponding regions of IgG1, the standard isotype for therapeutic antibodies, COMPLEGENT(TM) Technology significantly enhances CDC activity beyond that of either IgG1 or IgG3, while retaining the desirable features of IgG1, such as ADCC, PK profile and Protein A binding. In addition, it can be used together with POTELLIGENT(R) Technology, creating an even superior therapeutic Mab (AccretaMab(TM)) with enhanced ADCC and CDC activities.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd. (TSE:4151), Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa, BioWa is focused on development of ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases.

For more information about BioWa, visit its web site at www.biowa.com.

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs.

For more information about Medarex, visit its Web site at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "suggests"; "potential"; or "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. These risks and uncertainties include those detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

SOURCE BioWa, Inc.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880,
x2216, or
Nichol Harber, Corporate Communications (media),
+1-609-430-2880, x2214, both of Medarex, Inc.
Masamichi Koike, Ph.D., President and CEO of BioWa, Inc.,
+1-609-734-3420
Web site: http://www.biowa.com
http://www.medarex.com
(MEDX)

Pharmaceutical: Raptor Pharmaceuticals enters collaboration agreement

Novato, Calif., (ANTARA News/PRNewswire-AsiaNet) - Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the execution of a collaboration agreement (the "Agreement") with the University of California, San Diego ("UCSD") to include a Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate ("Cysteamine") in adolescents diagnosed with Non-Alcoholic Steatohepatitis ("NASH").

NASH is a progressive form of liver disease that accounts for approximately 10 per cent of newly diagnosed cases of chronic liver disease, and ranks as one of the leading causes of cirrhosis of the liver in the U.S.

Under the terms of the Agreement, clinical researchers from UCSD will perform the Phase 2a study at the University's General Clinical Research Center, and Raptor will provide funding and clinical supply of Cysteamine. In March 2008, Raptor acquired an exclusive, worldwide license to certain intellectual property and development rights from UCSD surrounding the use of Cysteamine as a potential treatment for NASH.

A rapid-release form of Cysteamine is currently approved for sale by the U.S. Food and Drug Administration ("FDA") for the treatment of nephropathic cystinosis, a rare, genetic lysosomal storage disease. Raptor is currently developing DR Cysteamine, a proprietary, delayed-release formulation of Cysteamine, designed to improve bioavailability and potentially reduce side effects associated with the presently marketed form.

Ted Daley, President of Raptor's clinical division stated, "We look forward to working with UCSD, one of the leading research universities in the nation, under this collaboration agreement. The University's clinical researchers have specific expertise in treating NASH patients, and have also worked extensively with Cysteamine. We are fortunate to work with this team to investigate our drug candidate's potential in this widespread liver disease.

NASH is a particularly significant unmet medical need with no current treatment options beyond diet and exercise. If this initial trial shows promising results, we will continue the development through an appropriate dosage form of our proprietary DR Cysteamine formulation for NASH patients."

NASH is believed to affect 2 per cent to 5 per cent of the U.S. population. While commonly diagnosed in overweight adults and children with and without insulin-resistant diabetes and abnormal serum lipid profiles, NASH can also occur in persons of average weight.

Though most people with NASH feel healthy and show no outward signs of liver disease, NASH causes liver scarring and potentially leads to cirrhosis and liver failure. In more severe cases, the progressive nature of NASH may require liver transplantation in affected patients.

Ranjan Dohil, Professor of Pediatrics at UCSD, commented, "The opportunity for DR Cysteamine in NASH could become a potentially significant breakthrough for these patients. Our collaboration with Raptor allows us to run this clinical trial by leveraging the University's resources and scientific capabilities with Raptor's instrumental support in funding, providing drug supply, and offering formulation expertise."

About Cysteamine and DR Cysteamine

Cysteamine is approved for sale by the FDA and European Medicines Agency to treat nephropathic cystinosis, a rare, genetic lysosomal storage disease. DR Cysteamine is designed as an improved, enterically coated, oral formulation of Cysteamine. Compared to the currently marketed formulation, DR Cysteamine could allow less frequent dosing, improving compliance and potentially reducing gastrointestinal side effects, such as nausea and vomiting.

Raptor obtained an exclusive, worldwide license to DR Cysteamine, as well as orphan drug designation from the FDA for DR Cysteamine for the treatment of nephropathic cystinosis, through its December 2007 merger of Encode Pharmaceuticals. In March 2008, Raptor acquired an exclusive, worldwide license to the intellectual property and development rights for use of Cysteamine and DR Cysteamine for the treatment of NASH. The Company plans to initiate a Phase 2a clinical trial in collaboration with the University of California, San Diego ("UCSD") to evaluate Cysteamine in patients with NASH. In May 2008, Raptor received orphan drug designation from the FDA for DR Cysteamine for the treatment of Huntington's Disease.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company leveraging novel drug-targeting platforms and reformulated therapeutics to improve treatment outcomes among patients with liver disorders, infectious diseases, cancer, and various orphan indications. The Company's clinical division advances internally developed and in-licensed clinical-stage product candidates towards marketing approval and commercialization and is currently involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTide(TM), WntTide(TM) and NeuroTrans(TM).

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor's ability to develop DR Cysteamine to improve bioavailability, reduce side effects and reduce dosage frequency; Raptor's ability to develop DR Cysteamine for the treatment of Cystinosis; Raptor's ability to develop an appropriate dosage form of DR Cysteamine for NASH patients; and Raptor's ability to formulate and manufacture DR Cysteamine in clinical quantities to support clinical trials. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form SB-2, as amended, that was declared effective on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on July 9, 2008, all of which are available free of charge on the SEC's web site at http:/ www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:
The Ruth Group
Sara Ephraim (investors) / Janine McCargo (media) +1(646) 536-7002/+1(646) 536-7033
sephraim@theruthgroup.com / jmccargo@theruthgroup.com

SOURCE: Raptor Pharmaceuticals Corp.
CONTACT: Investors, Sara Ephraim, +1-646-536-7002,
sephraim@theruthgroup.com, or
Media, Janine McCargo, +1-646-536-7033,
jmccargo@theruthgroup.com,
both of The Ruth Group, for Raptor Pharmaceuticals Corp.
Web site: http://www.raptorpharma.com

Technology: Canara Bank chooses Triple Point to manage new precious metals business

India's largest nationalized bank selects Commodity XL for Precious Metals to support complex business process workflows, rigorous risk management and regulatory compliance

Pune, India (BUSINESS WIRE) - Triple Point Technology?, the established leader in cross-industry commodity and energy trading, risk management, scheduling and logistics software solutions, announced today that Canara Bank, recognized as India's leading financial conglomerate with a client base exceeding 31 million, has chosen Commodity XL for Precious Metals? to manage its precious metals operation across 2,500 branches.

Canara Bank is India's largest nationalized commercial bank in terms of aggregate business volume, totaling approximately $40 billion USD in deposits. Headquartered in Bangalore, India, Canara was founded over 100 years ago and has a record of continuous profit since inception. The bank has over 2,500 branches across India and an international presence in London, Hong Kong, Moscow, Shanghai, Doha and Dubai.

New to the precious metals market, Canara required a solution that enabled rapid entry into the market and effective management of inventory, reconciliation, risk and regulatory compliance. Commodity XL for Precious Metals provides Canara with the competitive advantage of superior stock and inventory management, secure transaction processing and a real-time view of risk across the enterprise.

"The precious metals market has high price volatility, stringent regulatory?requirements and a complex physical supply chain; a solution must operate in real-time, integrate trading and logistics and support a robust risk management and compliance program," said Mike Ravo, vice president, industry solutions, Triple Point. Commodity XL for Precious Metals is the only software solution that provides seamless integration between supplier trading and retail bank operations, sophisticated inventory management from central consignment to point-of-sale, detailed regulatory reporting and an integrated approach to physicals, forwards and loans."

Commodity XL? is the leading commodity management solution and meets all the requirements for trading in today's highly volatile environment: multi-commodity capabilities, real-time integration of physical and financial positions, comprehensive risk management and the most advanced architecture. Comprised of a family of commodity-specific products that can be deployed alone or in seamless combination with each other, Commodity XL manages every aspect of global cross-industry supply, trading, marketing and logistics operations. Commodity XL for Precious Metals is based on ?METAGRID,' mature, market-proven technology obtained in Triple Point's acquisition of CoralGrid.

About Triple Point Technology Triple Point Technology is the established leader in cross-industry commodity and energy trading, risk management, scheduling and logistics software solutions. Triple Point Commodity XL? profitably integrates physical and financial markets from the front-to-back office on a real-time, next-generation platform for all commodities, including power, oil, gas, coal, base and precious metals, agricultural products, biofuels and freight. Triple Point's award-winning commodity and energy trading software solutions are used by more than 25 percent of both Global 500 commodity trading companies and Global 500 energy companies. Founded in 1993 and headquartered in Westport, Connecticut, USA, Triple Point serves clients from nine development and support centers located around the globe. More information is available at
www.tpt.com.

Triple Point Technology Jennifer Jones, 203-291-7979
x290jenniferj@tpt.com

Business in Asia Today - July 17, 2008

INDONESIA'S BUMI RESOURCES GAINS CONTROL OF HERALD RESOURCES
Perth (ANTARA News/Asia Pulse) - Indonesian coal miner Bumi Resources (JSX:BUMI) has secured control of Australia's Herald Resources Ltd (ASX:HER) after a rival suitor bowed out of a protracted bidding war for the lead and zinc hopeful on Tuesday. Bumi said in a statement today that it now holds a 51.34 stake in its target, up from 19.93 per cent earlier this week. Bumi's offer period has been automatically extended by 14 days and is now scheduled to close on July 30.
Bumi warned that shareholders who do not accept the offer before it closes - and Bumi holds a majority of Herald shares but is not entitled to proceed with compulsory acquisition - liquidity in Herald shares may be diminished.

MALAYSIA AIRLINES BUYS 35 BOEING PLANES WORTH US$2.6 BLN
Farnborough (ANTARA News/Asia Pulse) - Malaysia Airlines (MAS) (KLSE:3786) has ordered 35 Next-Generation Boeing 737-800 airplanes worth more than US$2.6 billion.
Malaysia's national flag carrier also has acquired purchase rights for an additional 20 Next-Generation 737-800s.
Boeing and MAS made the announcement at the Farnborough International Airshow in the United Kingdom on Wednesday.

INDIA'S BGR ENERGY BAGS US$1.1 BLN ORDER FOR RAJ THERMAL PJT
Mumbai (ANTARA News/Asia Pulse) - Indian engineering company BGR Energy (BSE:532930) today said the company has received an order worth Rp49 billion (US$1.1 billion) from Rajasthan Rajya Vidyut Utpadan Nigam for a thermal power project in the state. In a filing to Bombay Stock Exchange, the company said it has received an engineering, procurement and construction (EPC) contract for 2x600 MW Kalisindh thermal power project at Jhalawar, Rajasthan.
The scope of project includes engineering, supply of plant equipments and control systems.

SOUTH KOREA'S DC CHEMICAL WINS US$609 MLN POLYSILICON DEAL
Seoul (ANTARA News/Asia Pulse) - DC Chemical Co. Ltd. (KSE:010060), a South Korean chemicals producer, said Thursday it had signed a 613.7 billion won (US$609 million) contract with a Taiwanese silicon wafer company to supply polysilicon.
Under the contract with Sino-American Silicon Products Inc., DC Chemical will supply polysilicon from January 2010 to December 2016, an essential solar power component used for producing solar cells that convert sunlight into electricity, the Seoul-based company said in a filing to the Korea Exchange.

JAPAN'S MARUBENI IN US$315 MLN DEAL TO BUILD THAI POWER PLANT
Tokyo (ANTARA News/Asia Pulse) - Japan's Marubeni Corp. (TSE:8002) said Wednesday it has landed a contract to construct a natural-gas-fired power plant in Thailand.
The trading house won the order, valued at some 33 billion yen (US$315 million), with major US engineering firm Black & Veatch Corp.
The customer is Glow Energy Public Co., a major independent Thai power producer.

SHELL PHILIPPINES REQUESTS BACK UP FROM PNP DUE TO MASS ACTIONS
Manila (ANTARA News/Asia Pulse) - Oil giant Shell Philippines on Wednesday confirmed that it has beefed up its security and even requested additional back up from the Philippine National Police (PNP) to secure their office from possible militant actions.
Ed Chua, Shell country manager, said the series of militant actions had forced them to heighten security measures to ensure that no untoward incident will happen to their main office in Makati as well as their staff.
According to Chua they are willing to hold dialogue with the demonstrators to discuss and explain to them what was the reason behind the increases they are imposing on the prices of petroleum products.
Militant groups on Monday stormed the main office of Shell in Makati to protest the series of oil price hikes implemented by the firm.

JETSET SHAREHOLDERS APPROVE MERGER WITH QANTAS TRAVEL BUSINESSES
Sydney (ANTARA News/Asia Pulse) - Jetset Travelworld Ltd (ASX:JET) shareholders have voted in favour of a merger with Qantas Holidays and Qantas Business Travel.
Jetset chairman John King said in a statement after the company's extraordinary general meeting in Melbourne today that the vote paved the way for the merged entity to establish itself as one of Australia's leading integrated travel services groups. As a result of the merger, Jetset shareholders will receive a special dividend of 11 cents per share in August.
Under the deal, Jetset will acquire the Qantas businesses in exchange for scrip in Jetset.

HYUNDAI MOTOR UNION DEMANDS SEAT OF OUTSIDE DIRECTOR
Seoul (ANTARA News/Asia Pulse) - The union of Hyundai Motor Co. (KSE:005380) said Thursday it was demanding one of the seats on the automaker's board for outside directors so the union can play an active role in management and improvement of corporate governance.
The demand, which is expected to further complicate labor trouble at Hyundai this year, came a day before the 45,000-strong union plans to launch a six-hour partial strike, the fourth work stoppage this month, to press for higher pay and improvement of other labor conditions.
"Corporate transparency is a key for survival of both the management and the union," said a union official.

SIEMENS BAGS EQUIPMENT SUPPLY ORDER FROM TATA BLUESCOPE
New Delhi (ANTARA News/Asia Pulse) - The world's leading service provider for infrastructure facilities Siemens VAI Metals Technologies has bagged an order from Tata BlueScope Steel to supply equipment for the steel major's new processing lines at Jamshedpur.
The company has received the order to engineer, supply, erect and commission colour coating and hot-dipped zincalume lines from Tata BlueScope Steel, Siemens VAI Metals Technologies said in a release on its website.
Though not disclosing the order volume, the company said it is in the medium double-digit million euro range.
Tata BlueScope Steel, a 50:50 joint venture of homegrown Tata Steel (BSE:500470) and Australia's Bluescope Steel (ASX:BSL).

YAMAHA COMPLETES MOTORCYCLE WHEEL PRODUCTION SITE IN VIETNAM
Tokyo (ANTARA News/Asia Pulse) - Japan's Yamaha Motor Co. (TSE:7272) announced Wednesday it has constructed a motorcycle wheel manufacturing wing at its parts factory in Vietnam.
The company invested 1.5 billion yen (US$14.31 million) in the 9,000 square meter facility, which was built on the site of subsidiary Yamaha Motor Parts Mfg. Vietnam Co. in Hanoi.
Slated to go into service in September, the new addition will be capable of churning out 600,000 cast wheels a year for high-performance motorcycles.
Most of the cast wheels the company has sold in Vietnam to date have been procured from Indonesia and Taiwan.

Source:
Business in Asia Today - July 17, 2008
ppublished by Asia Pulse

Energy: EPV SOLAR, Inc., signs framework agreement with City Solar

EPV SOLAR, Inc., signs framework agreement with City Solar for the purchase of 250 MW of thin-film solar modules

Robbinsville, N.J. (ANTARA News/PRNewswire-AsiaNet) - EPV SOLAR, Inc. a thin-film solar module manufacturer and photovoltaic systems provider headquartered in New Jersey, USA, announced today that it has entered into a long-term solar module supply agreement with City Solar Kraftwerke AG.

City Solar, headquartered in Bad Kreuznach, Germany, is a tier-one international developer, installer and operator of large-scale photovoltaic power plants. The framework agreement allows City Solar to purchase 250 megawatts (MW) of amorphous silicon modules over a period of five years. City Solar plans to use EPV modules to further execute its growth strategy in Europe.

A first 2 MW project with EPV modules will be realized in Germany before the end of 2008. To meet the project schedule, EPV SOLAR has already begun to ship against this contract from its New Jersey manufacturing facility.

Later in the year, product will come from EPV SOLAR's new 30 MW/year thin-film PV products manufacturing facility in Senftenberg, Germany which is scheduled to begin production in the fall of 2008.

Both companies are committed to the wide-scale adoption of solar energy. To date, City Solar has connected to the grid projects with capacity of more than 81 megawatts (MW), including a 20 MW installation in Beneixama (Spain), which is one of the world's largest photovoltaic power plants.

Steffen Kammler, CEO of City Solar, commented: "We have selected EPV SOLAR as our commercial partner because of their reliable, low cost amorphous silicon technology. We are confident that EPV SOLAR's PV modules will deliver exceptional performance and value for our customers. City Solar looks forward to a long and prosperous relationship with EPV SOLAR and to expanding our partnership to include joint technology development and joint marketing efforts in other parts of the world."

"We are very pleased with this strong endorsement by City Solar of our thin-film technology and products. This new contract validates our strategy of partnering with tier-one integrators in Europe," stated Mr. Scott T. Massie, CEO of EPV SOLAR.

"We are committed to providing thin-film PV modules that achieve the lowest cost PV electricity in the world. Our goal is to help our customers achieve 'grid parity' on an accelerated time scale," Mr. Massie added.

Founded in 1991, EPV SOLAR is expanding its annual module manufacturing capacity to meet increased demand by its customers, including the demand under this contract. In addition to factories in Lawrenceville and Robbinsville, NJ, USA, EPV SOLAR expects to begin production at its Senftenberg facility in the fall of 2008. EPV SOLAR employs a vertically integrated model for the manufacture of thin-film solar modules, using its internally designed production equipment and batch manufacturing process. EPV SOLAR believes it enables a total installed system cost that is among the lowest in the industry.

SOURCE:
EPV SOLAR, Inc.
CONTACT:
Ren Jenkins, Vice-President, Marketing & Business
Development of EPV SOLAR, Inc.,
+1-609-587-3000 ext. 1114, cell +1-610-349-2286,
r.jenkins@epvsolar.com;
Stephan Brust, Press and Public Relations of City Solar,
+49 (0) 671 / 8 89 09 - 17, Fax +49 (0) 671 / 8 89 09 - 18,
stephan.brust@citysolar.de
Web site: http://www.epvsolar.com
http://www.citysolar.de

Pharmaceutical: South America - Pharma events confirmed for this year and 2009

Sao Paulo will host in 2009 after Rio debut this August

London (ANTARA News/PRNewswire-AsiaNet) - CMPi events for the fast-developing pharma markets of South and Latin America debut next month. Rio de Janeiro will host the twin launch of the CPhI South America pharma ingredients and P-MEC South America pharma machinery and equipment exhibitions on Tuesday 19 - Thursday 21 August. Sao Paulo will then host the 2009 events.

The launch exhibitions will be held at Brazil's newest convention facility - the Centro de Convencoes Sulamerica at Cidade Nova, opened last Summer. Main exhibition hours are 13.00 - 20.00.

Over 160 companies and organisations have booked to exhibit and the shows were fully sold a few months before the event.
Visitor registration and the latest exhibitor list for the twin events can be found via www.cphi-sa.com and www.pmec-sa.com.

Valued at approx. US$33bn., and with a 13 per cent growth rate - double the world average - the markets of Latin and Central America are joining China and India as regions of dramatic future opportunities for pharma-related services.

High interest in CPhI and P-MEC South America has already brought confirmation that the second year's exhibitions will be held on 26 - 28 August 2009, at Sao Paulo's Transamerica Expo Center.

Providing coverage across the pharma ingredients, contract services and production equipment sectors, co-location of CPhI and P-MEC will ensure a high level of networking and business opportunities in a single event visit.

To help market newcomers, the first event day (19 August) will feature the "First Latin American Pharma Business Forum". The six-session morning forum will provide a Latin America market overview, inform about the major requirements of business with and in Brazil, and import/export and regulatory requirements.

To connect buyers and sellers, "Match and Meet" networking sessions will be offered between 15.00 and 16.00 on 19 August and between 11.00 and 12.00 on the second and third event days.
Full programme details can be found at www.cphi-sa.com.
Deadline for online registration is Friday 25 July.

In a further networking benefit, the exhibitions coincide with Brazil's "6th Technical-Scientific Pharmaceutical Production Congress", also being staged at the convention centre over the same three days. Programme and registration details for the Congress -- the country's largest event of its type with 40 sessions across three tracks -- are at: www.pharmacongress.com.br. Note that the Congress language is Portuguese.

CMPi Pharma Portfolio Group Director Eliane van Doorn commented: "With 30 per cent of the market and an 18 per cent growth rate, Brazil is the natural host for the latest regional debuts of CPhI and P-MEC. Brazil enjoys a strong and growing presence by international market-leading companies, is a key regional manufacturing centre and increasingly important for clinical trials.
And she continued: "Following the success of both CPhI and P-MEC in India, events for the fast-growing South American markets -- including Mexico, Argentina and Venezuela -- were the logical next step in extending the brands. We've been delighted by the market reaction and strong bookings".

Key national organisations supporting the first CPhI and P-MEC South America events include: ABRIFAR -- the Brazilian Association of Importers and Distributors of Pharmaceutical Ingredients; ABIMIP -- the Brazilian Association of the OTC Medicine Industry; ABIQUIF -- the Brazilian Pharmochemical Producers Association; ABIFINA -- the Brazilian Association of the Fine Chemistry, Biotechnology and its Specialties Industries; Alanac -- the Association of National Pharmaceutical Laboratories; PRO-GENERICOS -- the Brazilian Association of the Industries of Generic Medicines and Sindusfarma - - the Pharmaceutical Industry Syndicate of Sao Paulo.

CPhI is the leading global event brand for pharma ingredients. P-MEC was created as a specific platform for pharma manufacturing machinery and equipment and launched in
Madrid in 2005, alongside CPhI Worldwide.

Notes for Editors:
Together, CPhI, ICSE and P-MEC provide integrated coverage of all main pharma services sectors. Held in Europe, CPhI Worldwide is the world's largest pharma ingredients event. The contract services and machinery events were added to meet
demand for dedicated exhibitions, but with critical mass and proven networking value of the CPhI brand.

-- CMP Information (CMPi) is the UK-headquartered B2B communications division of United Business Media plc (UBM). Operating internationally, CMPi delivers targeted integrated business media solutions to around 20 industry sectors.
Its products, including magazines, exhibitions, conferences, awards, information products and websites, target marketers, buyers and sellers across a range of markets. These include Construction and Architecture, Commercial Property, Food and Pharma Ingredients, Security, Interiors and Licensed Trade.

-- Amongst its well-established brands are industry-leading publications such as Building, Property Week, The Publican and Farmers Guardian. It also has a number of exhibitions recognised as the pre-eminent events in their respective market sectors; these include CPhI, The Interiors Event and IFSEC.

-- CMPi's magazines reach over 780,000 readers directly through subscription and controlled circulation. More than 330,000 business professionals and marketers visit its exhibitions each year. CMPi has approximately 1,200 employees in the UK, US, Asia and Europe and in 2007 generated over 190m pounds in revenues. See www.cmpi.biz

SOURCE CMPi
CONTACT: Gudrun Dohl (CPhI), +31(0)346-559-461,
or
Ian O'Malley (P-MEC), +31(0)346-559-426,
both of CMP Information;
or
Roger Johnstone of Gyro PR, +44(0)161-614-1450/
Web site: http://www.cmpi.biz

Business: AerCap announces completion of management transition

Amsterdam, and Miami (ANTARA News/PRNewswire-AsiaNet) - AerCap Holdings N.V. ("AerCap," NYSE:AER) announced that it has successfully completed its planned management transition at its AeroTurbine subsidiary.

Effective August 15, 2008, founders Nicolas Finazzo, CEO and Robert B. Nichols, COO, will be leaving their positions at the company. Mr. Finazzo will remain affiliated as a consultant to the Board of parent AerCap.

Michael King, 41, who is currently AeroTurbine's President, is being promoted into the CEO role, a transition that has been planned since he joined AeroTurbine in June 2006. Mr. King has over 15 years of aviation experience, having previously served as Group Vice President of Sales & Marketing at Chicago-based AAR Corp., and more recently as Senior Vice President-Materials at AeroTurbine.

"Michael King is most qualified to serve as CEO of AeroTurbine, Inc.," said Klaus Heinemann, Chief Executive Officer of AerCap.

"His strong aviation background, combined with his thorough understanding of the fundamentals of our business, ensures that this company will have strong leadership in the years ahead."

"We are proud to have been a part of one of the most dynamic aircraft engine leasing, trading and parts businesses in the industry. With the enlarged management team lead by Michael King, AeroTurbine is particularly well positioned to take advantage of opportunities in the aviation marketplace at this time," said Mr. Finazzo and Mr. Nichols.

As part of this transition plan AerCap recently made two further appointments to AerCap, Inc., its US subsidiary company managing all operations in the Americas.

Aengus ("Gus") Kelly, who has been with AerCap since 1998 and has held a number of senior management positions at the Company, was appointed CEO of AerCap, Inc. in November 2007 and Ray Valeika joined the Board of Directors of AerCap, Inc. effective January 1, 2008.

Ray Valeika is an internationally recognized senior airline operations executive, with over 40 years experience managing large airline maintenance operations. Mr. Valeika recently retired from the position of Senior Vice President - Technical Operations at Delta Airlines, where he was credited with establishing Delta Tech Ops, one of the industries leading MRO service providers, and directing a worldwide maintenance and engineering staff of more than 10,000 professionals, responsible for maintaining a fleet of close to 600 aircraft.

"Ray Valeika's experience over the course of his career with Delta, Continental and Pan Am brings a new dimension of industry insight and knowledge to the AerCap, Inc. Board. Together with the appointment of Gus Kelly as CEO of our operations in the Americas, this ensures that AerCap has a first rate management team in the Americas to face the challenges and to take advantage of opportunities that in particular the US market represents at this time," said Klaus Heinemann, Chief Executive Officer of AerCap.

About AerCap and AeroTurbine

AerCap is an integrated global aviation company with a leading market position in aircraft and engine leasing, trading and parts sales. AeroTurbine is a subsidiary of AerCap focusing on engine leasing and trading, airframe and engine disassembly, part sales and MRO services.

This press release may contain forward-looking statements that involve risks and uncertainties. In most cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of such terms or similar terminology. Such forward-looking statements are not guarantees of future performance and involve significant assumptions, risks and uncertainties, and actual results may differ materially from those in the forward-looking statements.

SOURCE: AerCap Holdings N.V.
CONTACT:
Media: Frauke Oberdieck, +31-20-655-9616,
foberdieck@aercap.com, or
Investors: Peter Wortel, +31-20-655-9658,
pwortel@aercap.com,
both of AerCap

Technology: Addintools releases easier Office 2007 upgrade

Hainan (ANTARA News/PRNewswire-AsiaNet) - Addintools Technology LTD announces the release of Classic Menu for Office 2007, an add-in for Microsoft Office 2007 Suite to provide easier upgrade experience and smoother learning and training curve to the users of previous versions of Microsoft Office. Classic Menu for Office 2007 replaces the controversial Ribbon of the Office 2007 user interface with classic menus and toolbars, offering upgrade 2007 while allowing users an upgrade experience when switching from previous versions of Microsoft Office. Classic Menu eliminates expensive training and allows users to feel immediately comfortable in the new Office by returning familiar classic menus and toolbars to Microsoft Office 2007 applications.

Classic Menu for Office 2007 supports all Office 2007 products and all languages and localizations supported by the Office Suite.

The new controversial Ribbon feature of the Microsoft Office 2007 GUI leaves many loyal users of previous versions of the Office Suite frustrated, as attempts to locate already accustomed features come back with trials and errors. Users also need to go through an expensive and time-consuming training in order to use the new product effectively.

Offering an accustomed user interface, 'familiar' does not mean 'old', as Classic Menu for Office 2007 supports all the new features added in Microsoft Office 2007, allowing users to access these new features in a convenient manner by using menus and toolbars instead of the Ribbon.

Enterprise users enjoy the simplified and streamlined upgrade path offered by Classic Menu for Office 2007. The product supports all applications of the Office, including Microsoft Word, Excel, PowerPoint, Access and Outlook 2007, and is localized into all languages supported by the new Office, including English, French, German, Italian, Spanish, Portuguese, Japanese, Chinese, and all the rest. The product offers a benefit of a smooth learning and training curve for all Office Suites, including Basic, Standard, Home and Student, Small Business, Professional, Professional Plus, Enterprise and Ultimate 2007 editions.

Evaluation version of Classic Menu for Office 2007 is available for free download at http://www.addintools.com/english/menuoffice/default.htm .

For more information, please contact:
Addintools Technology LTD
Lin Jie
Tel: +86-898-66768619
Email: support@addintools.com
http://www.addintools.com
SOURCE: Addintools Technology LTD

Mining/Minerals: Production of copper bonding wires to be increased substantially

New TCA 1 of copper bonding wire developed and launched

Tokyo (ANTARA News/PRNewswire-AsiaNet) - Tanaka Denshi Kogyo K.K. (Tokyo), the top manufacturer of bonding wires, will substantially expand the production of copper bonding wires with excellent electrical conductivity and mechanical properties at bonding, all at a much lower price, to meet increasing demand as a substitute for gold bonding wire, prices of which have been rising with the prices of gold bullion. It will also more vigorously promote sales for Taiwan and Singapore.

In order to achieve it, the company establishes new production lines in Singapore and in Saga in Japan, increasing 5 times as much the amount of monthly productions as what it is.

Tanaka Denshi Kogyo has also developed its new copper bonding wire, TCA 1, with equivalent performance to the gold bonding wire, and proactively tries to expand its share in the copper bonding wire market. Replacement with TCA 1 copper bonding wire allows material costs to be cut by two-thirds.

The new TCA 1 is copper bonding wire of 99.99 per cent purity, available in diameters ranging from Phi 20 micrometer - Phi 70 micrometer. Using the companys own processing technology, the characteristics of predecessors copper bonding wires were improved, yielding excellent mechanical properties (stable first bonding), electrical conductivity and surface characteristics.

The company has developed and produced multiple types of bonding wires, including gold, aluminum and copper, for various uses. Market shares in the world for gold and aluminum bonding wires are the highest, and copper bonding wire ranks second.

CONTACT:
Hiroshi Sato
Tanaka Kikinzoku International K.K.
Tel: +81-3-5222-1315
SOURCE Tanaka Kikinzoku International K.K.

Business: Arthur D. Little Strengthens Middle East Consultancy

ADL welcomes the expertise and regional experience of affinitives consultants to the consultancy's rapidly growing Middle East Practice

Dubai - Today leading global management consultancy Arthur D. Little announced that its Middle East office is integrating with the staff of Affinitiv, a strategic telecommunications and CRM consultancy with a strong presence in the region. Affinitiv's founder and CEO, Zoran Vasiljev, and his leadership team and employees will join Arthur D. Little's Middle East practice, with Vasiljev serving as a company Director.

Affinitiv celebrated its fourth year in operation in 2008, and has experienced greater-than-expected year-on-year growth since its inception. Bringing with them particular expertise in telecommunications and technology consultancy in emerging markets, the integration with Arthur D. Little will allow Affinitiv's consultants to bring new resources to their current client work and develop plans for continued growth within the region.

Michael Tram, Global CEO of Arthur D. Little, said: "Along with a shared focus on strategy, innovation and technology, Affinitiv's consultants share with ADL the capabilities, expertise and drive to cement our position in the growing Middle East marketplace."

Thomas Kuruvilla, Managing Director of Arthur D. Little Middle East, added: "I am delighted to begin work with Zoran and his team to respond to the rapidly growing demand from clients for experienced consultancy services in the region.
Access to a global network combined with local expertise is what has made ADL Middle East the company's fastest-growing
business unit.

We look forward to working with the Affinitiv team to continue this success and support ADL through this period of significant growth."

Speaking in Dubai, Vasiljev concluded: "Joining forces with ADL Middle East will provide a whole host of new opportunities for our clients and consultants. ADL is a major global player in strategic management consultancy, and with a growing brand
in the Middle East market, this integration is well positioned to promise continued growth."

It is anticipated that all Affinitiv staff will have joined Arthur D. Little Middle East by September 1, 2008.

About Arthur D. Little

Arthur D. Little (ADL), founded in 1886, is a leading global management consulting firm that links strategy, innovation and technology to master complex business challenges while delivering sustainable results to our clients. Arthur D. Little has a collaborative client engagement style, exceptional people and a firm-wide commitment to quality and integrity.

ADL is proud to serve many of the Fortune 100 companies globally in addition to many other leading firms and public sector organizations.

Arthur D. Little has over 30 offices worldwide, employing over 1,000 people. If you would like additional information on
the firm, please visit www.adl.com.

Say Communications for Arthur D. LittleSue Glanville /
Maita Soukup
Tel: +44 (0)208 971 6423 / 6421 Mobile: 077996 992853 /
07733 336216
sglanville@saycomms.co.uk
/ msoukup@saycomms.co.uk

Technology: XML Technology Certification Committee announces a new certification

The XML Technology Certification Committee announces a new certification for XQuery and XML DB technical expertise

Tokyo - /Kyodo JBN-AsiaNet/ - The XML Technology Certification Committee today announced the worldwide release of the "XML Master Professional Database Administrator" exam, certifying technical professionals in XQuery and XML DB.

The new "XML Master Professional Database Administrator" certification is designed for database professionals, who must pass the "XML Master Basic Exam" and the "XML Master Professional Database Administrator Exam" to become certified.

The "XML Master Professional Database Administrator Exam" is comprised of four sections dealing with (1) Overview; (2) XQuery and XPath; (3) Manipulating XML Data; and (4) Creating XML Schema and Other XML Database Objects. The exam takes 90 minutes, and the passing score is 80%. The XML Master Professional Database Administrator exam is available beginning today at Prometric's global network of over 4,700 test centers.

In conjunction with today's announcement, the XML Technology Certification Committee has also announced a name change for the XML Master Professional Certification. The certification will now be known as the "XML Master Professional Application Developer Certification."

About the XML Certification Program - XML Master The "XML Master" is a professional certification officially launched in August 2001. The primary objective of the "XML Master" is the broad-based development of professionals having XML skills. To date, more than 16,000 professionals throughout the world have become XML Masters.

XML Master Success Stories: http://www.xmlmaster.org/ensuccess/ For more, please see: http://www.xmlmaster.org/en/

About Prometric Prometric, a wholly-owned subsidiary of ETS, is the recognized global leader in technology-enabled testing and assessment services and the winner of CLO Magazine's Learning in Practice 2007 Customer Service Award. Its comprehensive suite of services, including test development, test delivery and data management capabilities, allows clients to develop and launch global testing programs as well as accurately measure program results and data. Prometric reliably delivers and administers tests on behalf of 450 clients in the academic, professional, healthcare, government, corporate and information technology markets. It delivers tests flexibly via the Web or by utilizing a robust test center network in 135 countries. For more information, please visit www.prometric.com.

Source: XML Technology Certification Committee
Contact: Kaoru Shima XML Technology Certification Committee
TEL: +81-3-5718-1297 For news article usage:
office@xmlmaster.org Web site: http://www.xmlmaster.org/en/

Business: ASF SE revises offer price for BASF India shares

Mumbai, (ANTARA News/PRNewswire-AsiaNet) - BASF SE today announced that it has revised its offer price for shares in BASF India, to Rs. 300 per share. The revised price provides a compelling premium of 26.7 percent above the minimum price directed by the Securities and Exchange Board of India (SEBI), 33.4 percent above the average share price for the two weeks preceding the date of the original announcement.

BASF SE will pay the revised offer price for all the equity shares validly tendered any time during the offer if accepted under the offer. In line with current regulations, this represents the final revision of the offer.

In May 2008, BASF SE announced that it intended to acquire 22.31 percent of shares in BASF India Limited, through a public tender offer to shareholders, at a price of Rs. 274 per share. This would raise its holdings to a maximum of 75 percent, from its current holding of 52.69 percent. According to the public announcement, the offer began on July 9, 2008 and shareholders have until July 28, 2008 to tender their stock.

BASF India Ltd., which is traded on the Mumbai stock Exchange and National Stock Exchange of India (Mumbai), posted sales of INR10,536.4 million in the business year ended March 31, 2008. The main chemical markets for BASF in India are agrochemicals, plastics, leather and textile chemicals.

About BASF

BASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from oil and gas to chemicals, plastics, performance products, agricultural products and fine chemicals. As a reliable partner BASF helps its customers in virtually all industries to be more successful. With its high-value products and intelligent solutions, BASF plays an important role in finding answers to global challenges such as climate protection, energy efficiency, nutrition and mobility. BASF has more than 95,000 employees and posted sales of almost 58 billion in 2007. Further information on BASF is available on the Internet at http://www.basf.com.

Genevieve Hilton (Hong Kong)
Phone: +852-2731-0197
Fax: +852-2731-5645
genevieve.hilton@basf.com
Stella Chiu (Hong Kong)
Phone: +852-2731-1228
Fax: +852-2734-9645
ngachi-stella.chiu@basf.com
Michael Grabicki (Germany)
Phone: +49-621-60-99938
Fax: +49-621-60-92693
michael.grabicki@basf.com
BASF SE
67056 Ludwigshafen, Germany
Phone:+49-621-60-0
http://www.basf.com
Corporate Media Relations
Phone: +49-621-60-20916
Fax:: +49-621-60-92693
presse.kontakt@basf.com
Source: BASF SE

Pharmaceutical: Galderma announces approval for Differin(R) Gel 0.1% in Japan

Based on the largest ever clinical program for Acne in Japan

Lausanne (ANTARA News/PRNewswire-AsiaNet) - Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, announced today that Japan's Ministry of Health, Labor and Welfare has approved Differin(R) Gel 0.1% (adapalene), a novel topical treatment for acne vulgaris in Japan. The drug will be marketed in Japan by Galderma KK, the fully-owned Japanese arm of Galderma, and strategic alliance partner Shionogi.

Differin(R) has been available for over 15 years and is currently marketed in more than 80 countries, where it has become an important therapy for more than 22 million patients.(1) Approval in Japan will reinforce Galderma's presence in the world's second-largest pharmaceutical market.
Approval was based on non-clinical and clinical studies, which supported the efficacy and safety of the product for the registration outside Japan and on an extensive local clinical development program, including two phase 3 studies enrolling more than 600 Japanese patients.

A 12-week study of the treatment in 200 Japanese patients(2a) a demonstrated that treatment with Differin(R) Gel 0.1% led to a significant reduction in both inflammatory and non-inflammatory lesions, as compared with vehicle treatment, with some patients feeling the benefit after only one week of treatment.(2b) A 12-month long-term safety study of more than 400 patients(3) a showed that the treatment was safe and remained effective with long-term use.(3b)

"The collective results of three recent adapalene studies provide a substantial evidence base for the safe and effective use of adapalene gel 0.1% in Japanese patients with acne," said Clinical Trial Lead Investigator Makoto Kawashima, MD, PhD Department of Dermatology Tokyo Women's Medical University.
"The availability of a topical retinoid in Japan will provide greater flexibility for customizing care and improving outcomes for acne patients."

According to the agreement between both firms, Galderma and Shionogi will co-promote Differin(R) Gel 0.1% with their respective sales forces and Shionogi will have sales and distribution rights for the product for a period of eight years. Commercialization will begin once the product is listed on the National Health Insurance reimbursement list, a process that is expected to be complete by autumn 2008.

"The decision by Japan's Ministry of Health, Labor and Welfare is excellent news for patients and physicians in Japan, who will now have access to a first-in-class topical retinoid for the treatment of acne," said Humberto C. Antunes, Chief Executive Officer of Galderma International. "We undertook the largest acne clinical program ever in Japan, and knew it would be a long journey to approval. This project underscores Galderma's commitment to dermatology in all parts of the world and dedication to improving the quality of life of acne patients in Japan."

Differin(R) Gel 0.1% is a naphthoic acid derivative with retinoid-like activities.(2c) Differin(R) will be the first product to be launched in Japan belonging to this class of treatment. Differin(R) appears to normalize the differentiation of a type of skin cell linked to acne, resulting in fewer
non-inflammatory and inflammatory lesions.(2c)

About Acne

Acne vulgaris is one of the most widely experienced chronic skin diseases worldwide. In recent years, research has led to a greater understanding of the pathogenesis of the disease.(4) The disorder begins with the onset of puberty and is thought to result from hormonal action on the skin's oil glands (sebaceous glands) leading to plugged pores and outbreaks of spots.(5) It can be challenging to manage, due to the variability in response to treatment.(2d)

About Galderma Japan

Galderma KK, the fully-owned Japanese arm of Galderma, was established in 1996. It has been marketing the topical anti-fungal product Pekiron(R) Cream 0.5% (Loceryl(R)) under a licensing agreement with Kyorin Pharmaceutical since 2002. With the introduction of Differin(R) Gel 0.1% in Japan, Galderma KK, aims to provide comprehensive scientific information to prescribers and medical institutions, with the goal of improving treatment outcomes, as well as the quality of life of Japanese acne patients.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company is present in 65 countries with over 1000 medical sales representatives and is committed to improving the health of skin with an extensive line of products to treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancers and medical solutions for skin senescence. With a main research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities devoted exclusively to dermatology. Leading dermatology brands include Differin(R), MetroGel(R) 1% Rozex(R), Oracea(R), Clobex(R), Tri-Luma(R), Loceryl(R) and Cetaphil(R). Recently launched products include Pliaglis(R), a topical anesthetic for dermatologic procedures in the United States, Epiduo(R), an innovative combination product for the treatment of acne in Europe and Argentina, and Dysport(R), an injectable muscle relaxant for use in aesthetic medicine and dermatological indications in Brazil and Argentina. The
Company's international Web site is http://www.galderma.com.

Differin, MetroGel, Oracea, Rozex, Clobex, Tri-Luma, Loceryl, Cetaphil and Epiduo are trademarks of Galderma.

Pliaglis is a trademark of Zars Pharma Inc.
Dysport is a trademark of Ipsen Ltd.
(1) Data on file.
(2) Kawashima M, Harada S, Loesche C and Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris:
A
randomized, multicenter, investigator-blinded, controlled study.
Journal of Dermatological Science. 2008; 49:241-248.
(3) Kawashima M, Harada S, Andres P and Miyachi Y. One-Year Efficacy and
Safety of Adapalene Gel 0.1% gel in Japanese Patients with Acne
Vulgaris. Skin Research. 2007; 6:504-512.
(4) Gollnick H, Cunliffe WJ, Berson D et al. Management of Acne: A Report From a Global Alliance to Improve Outcomes in Acne. J Am Acad
Dermatol. 2003; 49(1):S1-S37.
(5) Why Do I Get Acne? Nemours Foundation.
http://www.kidshealth.org/teen/your_body/skin_stuffacne.html.

SOURCE: Galderma Pharma S.A.
CONTACT: Worldwide Inquiries,
Alain Kirsch,
+33 (0) 1 58 86 43 23,
alain.kirsch@galderma.com;
or U.S. Inquiries,
Dale Weiss,
+1-817-961-5186,
dale.weiss@galderma.com,
both of Galderma Pharma S.A./
Web site: http://www.galderma.com

Business: Hirsch's strong growth in Asia-Pacific spurs additional investment

Hirsch Electronics taps veteran Ross Head as Asia-Pacific Divisional Manager

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-binmmg.cgi?eid=5733372

Santa Ana, Calif. (BUSINESS WIRE) - Hirsch Electronics, a leading supplier of access control and security management solutions, announced today the hiring of Ross Head for the newly created position of Asia-Pacific Divisional Manager. Mr Head will be responsible for supporting existing Hirsch partners and dealers, establishing new relationships, and managing sales in the region. He is based in Cleveland, Queensland, Australia, and reports to John Piccininni, Hirsch vice president of sales.

"We are thrilled to have Ross back with Hirsch,"commented Mr Piccininni, reflecting on Mr Head's many years as a Hirsch employee and dealer. "His intimate knowledge of Hirsch solutions offers our dealers and end-user customers the expertise necessary to successfully educate prospective partners and customers, develop new business, and provide his unique perspective as a former dealer himself."

Mr Head was national sales manager for Hirsch Electronics until 2003 when he left to join a Hirsch dealer as vice president sales & marketing. He recently returned to his native Australia as senior manager with PricewaterhouseCoopers.

Hirsch Electronics has developed an extensive international distribution network during the past twenty-seven years operating in the global market. The appointment of Mr Head to manage the Asia-Pacific division, combined with the opening of a Europe, Middle East and Africa (EMEA) office in 2006, represents Hirsch Electronics' continued investment and commitment to the customers, partners and dealers that market and use Hirsch's award-winning access control and security management systems around the world.

NOTE: For a high-resolution image of Ross Head, please download - http://www.riccicom.com/clients/heRoss_Head.jpg

About Hirsch Electronics Hirsch Electronics manufactures physical security systems for worldwide markets.
Hirsch is a recognized leader in IP-based security solutions that interoperate with other networked databases, devices and systems.

Hirsch's award-winning role-based access control (RBAC), identity management, and security management systems integrate access control, digital video, alarm monitoring, smart cards and biometrics. Hirsch security solutions are IT-centric, highly secure, and scalable to even the largest organizations.
Hirsch Electronics' headquarters are at 1900-B Carnegie Avenue, Santa Ana, California, 92705, U.S.A., Phone: +1-949-250-8888, E-mail: info@hirschelectronics.com; Website: www.HirschElectronics.com.

Hirsch Electronics
Scott Howell, +1 949-250-8888 ext. 130
marketing@hirschelectronics.com
or Ross Head, +61 7 3472-1346
rosshead@hirschelectronics.com

Technology: Palomar Establishes Subsidiary in Australia

Burlington, Mass. (ANTARA News/PRNewswire-AsiaNet) - Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for cosmetic treatments, today announced the establishment of an international sales office in Australia to support Palomar's efforts in gaining market share and assist with sales, service and marketing in Australia and New Zealand.

Joseph P. Caruso, Palomar Chief Executive Officer said, "To provide direct service support to our current customers, and offer an exciting benefit for new customers, we are pleased to announce the opening of this new office to assist in marketing and provide easy access to clinical information to all. The direct availability of Palomar products and service support in this region will further enhance Palomar's brand recognition and provide access to a wide variety of superior aesthetic
treatment modalities to better meet customer needs. To further support our customers, we will also be looking to focus on ongoing educational clinical symposiums, consensus meetings and collaborative marketing campaigns."

Mr. Caruso continued, "Palomar remains committed to developing new technologies for products that provide superior results, and we look forward to the placement of our new Aspire(TM) aesthetic laser platform and SlimLipo(TM) laser-assisted lipolysis handpiece in the near future. The Aspire platform will allow Palomar to offer new high-demand body sculpting procedures and complement the broad range of aesthetic applications offered by Palomar's flagship StarLux(R) 500 laser and pulsed-light platform. With a focused approach to the market and a highly specialised sales and support team, we are confident of maintaining and enhancing our leadership position in this flourishing region."

About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

For more information on Palomar and its products, visit Palomar's website at http://www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

Contacts: Dennis Cronje
Director of Operations
Palomar Medical Technologies (Australia) Pty Ltd.
Phone: +61401823775
Email: dcronje@palomarmedical.com

SOURCE Palomar Medical Technologies, Inc.
CONTACT: Dennis Cronje, Director of Operations of Palomar
Medical Technologies (Australia) Pty Ltd., +61401823775,
dcronje@palomarmedical.com
Company News On-Call: http://www.prnewswire.com/comp
107555.html
Web site: http://www.palomarmedical.com

Security: Hazel Blears to speak at Fire & Rescue 2008

Fire & Rescue Exhibition & Conference 2008 - 27-29 August 2008 - ACC Liverpool

London (ANTARA News/PRNewswire-AsiaNet) - The Rt Hon Hazel Blears MP, Secretary of State for Communities and Local Government will present the closing keynote address at the annual Fire & Rescue Conference on 28 August 2008 at the newly built Arena and Convention Centre (ACC) in Liverpool. Ms Blears will also take a tour of the accompanying exhibition and visit the co-located World Firefighters Games. The conference will take place at Fire & Rescue Exhibition & Conference 2008, from 27-29 August 2008 at the ACC Liverpool.

Ms Blears comments, "Our fire and rescue service continues to be dynamic and we should actively pay tribute to all our fire and rescue staff who work tirelessly to make our communities safer places to live and work. I'm looking forward to visiting the Fire & Rescue 2008 Exhibition and Conference, where I hope to meet as many members of the fire service as possible."

The Fire & Rescue 2008 conference is an acknowledged platform to debate current fire and rescue issues and long-term trends and developments. The conference is a "must-attend" event for all senior UK and international fire officers as well as locally elected government officials and representatives from the fire prevention industry. The 2008 programme will feature a number of issues currently high on the national agenda such as operational doctrine, flooding, health and safety, comprehensive area assessments, fire insurance, sprinklers as well as equality and diversity.

The speaker panel will also include some of the industry's foremost leaders and opinion shapers with distinguished names such as Bob Neill MP, Shadow Minister for Local Government; Sir Michael Pitt, author of the Pitt Review; Bill Stewart, US Metro Chief President; Brigadier Richard Dennis, Director of British Infantry; Ann Jones, AM of the Welsh Assembly; and Roy Watkinson, Technical & Commercial Director at AXA Insurance.

Representatives from fire and rescue services around the UK will be presenting conference sessions, including representatives from South Yorkshire, Hereford & Worcester, Luton & Bedfordshire, Greater Manchester and Lancashire.

The main plenary sessions will be supported by FCEL's usual programme of highly topical and practical workshops, which this year will cover new technology, skills and competency framework, industrial relations, national standards and interoperability, and post-fire business continuity.

Run on behalf of the Chief Fire Officers Association (CFOA), the Institution of Fire Engineers (IFE) and the Fire Protection Association (FPA), and in partnership with Merseyside Fire and Rescue Service, hosts of the World Firefighters Games 2008, Fire & Rescue 2008 will cater for the requirements of everyone within the Fire & Rescue Service, from senior and operational level officers through to management level support staff.

The exhibition will host over 150 of the leading suppliers to the Fire & Rescue Service including, AssetCo plc, Draeger, Trelleborg, Bristol Uniforms, VectorCommand, Cosalt, EADS, MFC Survival, Hale Products Europe. Many of these companies will be launching new and innovative products into the market for the very first time.

Spectacular live action displays will take place throughout the duration of the show, where visitors will witness real time demonstrations showing current techniques for firefighting scenarios, such as urban search and rescue, vehicle rescue and water rescue, hosted by Merseyside Fire & Rescue.

Fire & Rescue 2008 will take place from 27-29 August 2008 at the ACC, Liverpool and will be co-located with the World Firefighters Games 2008. For further information on the event or to see the full conference programme, please visit www.fireandrescueexpo.com. Companies interested in exhibiting should contact Ana Monteiro on +44 (0) 20 7921 8164 or amonteiro@cmpi.biz.

About CMP Information

Operating internationally, CMPi delivers targeted integrated business media solutions to around 20 industry sectors. Its products, including magazines, exhibitions, conferences, awards, information products and websites, target marketers, buyers and sellers across a range of markets; these include Construction and Architecture, Commercial Property, Food and Pharma Ingredients, Security, Interiors and Licensed Trade.

Amongst its well-established brands are industry-leading publications such as Building, Property Week, The Publican and Farmers Guardian. It also has a number of exhibitions recognised as the pre-eminent events in their respective market sectors; these include CPhI, The Interiors Event and IFSEC.

CMPi's magazines reach over 780,000 readers directly through subscription and controlled circulation. More than 330,000 business professionals and marketers visit its exhibitions each year. CMPi has approximately 1,200 employees in the UK, US, Asia and Europe and in 2007 generated over #190m in revenues.

SOURCE CMP Information
-0-
07/16/2008
/NOTES TO EDITORS: 1. The Rt Hon Hazel Blears MP will speak at the event closing at 3:15pm on 28 August 2008 at the ACC
Liverpool. 2. If you would like a press pass to attend the event, please contact Jo Hudson on +44(0)20-7921-8067. 3.
Photography is available to accompany this release. If you would like to receive a selection of images please email
johudson@cmpi.biz./

CONTACT: Jo Hudson, PR & Communications Executive of
Protection & Management Portfolio of CMP Information Ltd,
+44(0)20-7921-8067, fax +44(0)20- 7921-8059, johudson@cmpi.biz
Web site: http://www.fireandrescueexpo.com/

Business: A.M. Best affirms ratings of credit & gGeneral iInsurance limited

Oldwick, N.J. (BUSINESS WIRE) - A.M. Best Co. has affirmed the financial strength rating of A-(Excellent) and issuer credit rating of "a-" of Credit & General Insurance Limited (CGIL) (New Zealand).

The outlook for both ratings is stable.

The ratings reflect CGIL's conservative risk-adjusted capitalization, consistent operating performance and strong liquidity. The ratings also consider the company's exclusive distribution arrangement with the Farmers retail chain, one of the largest retail department stores in New Zealand.

CGIL's low claims experience and cautious expense control resulted in continual emergence of underwriting earnings in 2008. CGIL lowered its expense ratio to 37.3% in 2008 from 45.9% in 2007 due primarily to the reduction in acquisition costs. Its insurance book continued to record a favorable loss experience, although the overall premium volume on an absolute basis remained relatively small.

Strong underwriting performance along with a stable investment yield led to a consistent surplus growth, translating into a further improvement in CGIL's risk-adjusted capitalization in 2008. Best's Capital Adequacy Ratio (BCAR), which measures capitalization on a risk-adjusted basis, reflects that the company maintained a solid capital position supportive of its ratings. In view of CGIL's stable operating profitability and moderate business growth, A.M. Best anticipates that the company will maintain a relatively conservative level of risk-adjusted capitalization in the near term.

CGIL's investment portfolio was liquid, with cash and money market deposits representing more than 95% of its assets at year-end March 2008. Investment assets to total liabilities increased to 13.4 times in 2008 from 10.9 times in 2007. A.M.
Best anticipates CGIL's investment portfolio to remain conservative and highly liquid in the near term.

Offsetting rating factors include CGIL's business concentration risk in the consumer credit sector and limited insurance growth prospects.

CGIL's operating results are subject to the performance of the economy and consumer credit market in New Zealand.

Given that CGIL predominantly relies on Farmers as its core distribution channel, the company's business growth is heavily dependent upon the operating performance of Farmers' retail business. CGIL's narrow product range, along with concentration risk in its distribution channel, could limit its growth prospects.

For Best's Ratings, an overview of the rating process and rating methodologies, please visit www.ambest.com/ratings.

Founded in 1899, A.M. Best Company is a global full-service credit rating organization dedicated to serving the financial
and health care service industries, including insurance companies, banks, hospitals and health care system providers.
For more information, visit www.ambest.com.

A.M. Best
Analysts
Billy Wong, +852-2827-3414 billy.wong@ambest.com
or Terrence Wong, +852-2827-3403 terrence.wong@ambest.com
or Public Relations
Jim Peavy, +(1) 908 439 2200, ext. 5644
james.peavy@ambest.com
or Rachelle Morrow, +(1) 908 439 2200, ext. 5378
rachelle.morrow@ambest.com

Apparel/Textile: MBI Technology introduces circular-type intarsia knitting machine

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-binmmg.cgi?eid=5732482

Seoul,South Korea (BUSINESS WIRE) - MBI Technology Co., Ltd, a global manufacturer of intarsia sweater knitting machines, announced today that they have developed a new intarsia knitting machine for intarsia sweaters with the maximum 42 color change in single course. The new intarsia knitting machine is named MBI-S1342 and will be available in domestic and international markets.

Using the world's first circular type and circular knitting machine structure for mass-production of knits, MBI-S1342 can coordinate on knitting body and rib border, continuous knitting, and small quantity batch production of any desired designs through computer design programs.

MBI-S1342 has a diameter of 25.1 inch, standard 13 gauges with variable gauges from 12 to 14, and 42 feeders for intarsia and 2 feeders for rib border. The feeders for intarsia and rib border in MBI-S1342 provide a variety of intarsia designs and produce any size of knits in a short lead time.

Since MBI-S1342 uses circular type, its needle cylinders rotate reciprocally back and forth, which provides an excellent expression of any detailed patterns such as vertical stripes, curves, and thin lines.

MBI-S1342 also runs with Easy Graphic Design System based on Windows, therefore anyone can easily create their own design, save them in USB devices, and load the design on the machine through its USB port. Once the design is loaded in the program, the machine will automatically begin the knitting for intarsia pattern.

Denny Y. D. Koo, vice president of MBI Technology, commented about the new machine, "We are hearing a lot of positive feedback about our new MBI-S1342 from the market research and prospects especially in European and Asian sweater manufacturing industry.""We proudly recommend MBI-S1342 as one of the necessary machines for fashion sweater manufacturers who want development of classy and value added sweater products," he added.

About MBI Technology Co.,Ltd.

MBI technology was established in 2003 as it succeeded the 20 years of fabric industry experience from E-STAR Co., Ltd.
Since the new establishments, MBI Technology has been focusing on developing and manufacturing new fabric machines for the global market. For more information, please visit www.mbitec.com.

MBI Technology Co.,Ltd.
Denny Y. D. Koo, +82-31-542-9542 intarsia@mbitec.com

Insurance: A.M. Best affirms ratings of consumer insurance services limited

Oldwick, N.J. (BUSINESS WIRE) - A.M. Best Co. has affirmed the financial strength rating of A- (Excellent) and issuer credit rating of "a-" of Consumer Insurance Services Limited (CISL) (New Zealand). The outlook for both ratings is stable.

The ratings reflect CISL's consistent operating profitability and improvement in risk-adjusted capitalization.

The ratings also acknowledge CISL's operational synergy derived from the financing activities of Fisher and Paykel Finance Limited (F&P Finance).

A reduction in underwriting risk as a result of a fall in net premiums written led to an increase in CISL's risk-adjusted capitalization, as measured by Best's Capital Adequacy Ratio (BCAR), for the year ended March 2008.

Nonetheless, CISL's capital and surplus on an absolute basis recorded a slight improvement of 2.3% to NZD 5.3 million in 2008.

CISL continued to sustain its solid operating profitability through maintaining favorable claims experience and growing its administrative earnings. Despite the decrease in direct insurance business, income from administrative warranty grew to NZD 1.9 million (USD1.5 million) for fiscal year 2008, representing 57.8% of the company's pre-tax operating income.
CISL produced an overall net income of NZD 2.2 million (USD1.8 million), equivalent to a 41.8% return on equity. With the emergence of warranty income and stable claims experience, CISL is expected to maintain sound operating results in the near term, although the expense ratio will remain relatively high.

Offsetting rating factors include CISL's business concentration risk in the consumer credit market, decline in business volume and high dividend payout requirement.

Given CISL's primary focus in the consumer credit insurance product, its underwriting result is heavily dependent on the consumer credit market's profile. A change in payment method of the underlying loan led to a 24.1% decline in direct insurance business in 2008. A further shift in consumer loan payment preference could potentially translate into earnings volatility for CISL going forward, although the company has plans to launch a new initiative to diversify its income sources.

As a result of the high dividend payout requirement by its parent, CISL paid 97.9% of the company's net earnings over the
past five years, greatly limiting its internal surplus growth.

Nonetheless, A.M. Best believes that F&P Finance will provide ongoing capital support to CISL should the business need arise.

For Best's Ratings, an overview of the rating process and rating methodologies, please visit www.ambest.com/ratings.

Founded in 1899, A.M. Best Company is a global full-service credit rating organization dedicated to serving the financial and health care service industries, including insurance companies, banks, hospitals and health care system providers.
For more information, visit www.ambest.com.

A.M. Best Co.
Analysts
Billy Wong, +852-2827-3414 billy.wong@ambest.com
or Terrence Wong, +852-2827-3403 terrence.wong@ambest.com
or Public Relations
Jim Peavy,+(1) 908-439-2200, ext. 5644
james.peavy@ambest.com
or Rachelle Morrow,+(1) 908-439-2200, ext. 5378
rachelle.morrow@ambest.com

Business: Hyderabad opens the gateway to fine jewellery in South India

Hyderabad (ANTARA News/PRNewswire-AsiaNet) - There's excitement in the air as the Hyderabad Jewellery, Pearl & Gem Fair 08,(HJF) comes to Hyderabad.

If you are wondering what the buzz is all about, this will be the first ever largest international Jewellery fair in South India and will bring the best of Indian and International Jewellery under one roof.

Over 150 exhibitors occupying 250 booths are spread over 10000 sqmtrs., of show floor.

HJF has special group pavilions from Thailand and Hong Kong.
Apart from India, overall HJF has confirmed participation from 15 countries and regions including Taiwan, Italy, Burma, Japan, Belgium, Israel, Turkey, Belgium, and Middle East.

"South India is not only the country's major consumer market for Jewellery of all types but also a major manufacturer of Jewellery and a Gem and Pearl processing and trading centre, with long-established national and international centers.

"HJF'08 also aims to provide an international platform for buyers and sellers of fine jewellery, pearls, diamonds, gems and other precious materials to meet at the peak of the buying cycle of the festive season," says M. Gandhi, Managing Director, CMP India (UBM India) - the organizer of HJF '08.

When it comes to fine jewellery in South India, Hyderabad is one of the first cities to come to the mind.

And for good reason, the exquisite Nizam's jewels rank amongst the world's finest. The city is also known for its rich craftsmanship and rare and exquisite gemstone and pearl Jewellery.

Some of the world's most famous diamonds like the Kohinoor, Regent and Hope are from Andhra Pradesh.

South India is the biggest jewellery market in the country and Hyderabad with its infrastructure and facilities is the ideal location for the Hyderabad Jewellery, Pearl & Gem Fair, (HJF'08).

The exhibition is scheduled from the 24th to 27th July, 2008 at the HITEX Exhibition Centre.

It will coincide with the onset of the festive season and is bound to attract thousands of visitors from India and overseas.

What makes HJF'08 unique is that it will be both a B2B as well as a B2C event and will cater to both the targets.

It will function as an international trading platform which will facilitate domestic and overseas jewellery, diamond, pearl and gemstone suppliers to meet key buyers and open up new vistas of opportunities.

The show will offer an opportunity to view a large range of jewellery from India and overseas right here in south of India.

An international delegation from China and various countries are already confirmed to visit the event.

Besides the domestic jewellery associations, have also confirmed their member are planning to visit the event in large numbers to strike suitable business partnerships.

For the consumer, this will be an opportunity to discover a whole new world of designer jewellery in fascinating designs and styles like never before.

They will be able to pick world class jewellery showcased in a luxurious setting where they can shop in comfort.

Various marketing efforts have been used very effectively to reach the quality business visitors, through E-newsletters, PR support, direct mailing and other promotional activities.

Road shows in Hyderabad, Kochi, Thrissur, Trivandrum, Vishakhapatnam, Kakinada, Rajahmundry, Vijayawada, Guntur, Chennai, Coimbatore Salem and Nellore have already been organised to promote the event.

CMP is the organizer and owner of several global jewellery trade fairs, including Asia's biggest international jewellery trade fair, the September Hong Kong Jewellery & Watch Fair, which is held annually.

This fair attracts 40,000 visitors from 140 countries and regions, and over 2,400 exhibitors from 47 countries and regions.

CMP is organizing HJF'08 with the support of the Twin Cities Jewellers Association, Hitech City Jewellery Manufacturers Association and A.P. Gold, Silver, Jewellery & Diamond Merchants Association, Jewellery Manufacturers Association -Kerala.

With its international expertise and knowledge of markets, CMP is all set to make HJF'08 a successful show.

About CMP India

CMP India, a part of CMP Asia, is owned by United Business Media Limited, one of the world's leading global business information companies.

The company's businesses include trade exhibitions across various sectors such as pharmaceuticals, food ingredients, hospitality, security, jewellery & technology sectors, conferences, online technology & print brands, health care communications and news distribution.

Globally this translates into more than 200 newspapers, magazines and directories, 200 websites and 300 events around the world.

SOURCE: CMP India
CONTACT: C. Bhaskar,
bhaskarc@ubmindia.com,
+91-9820-501-620, for CMP India/

Business: China's new world hotel partners with Luxe worldwide

China's prestigious new world hotel group selects Luxe Worldwide Hotels for international representation: major signing ceremony in Hong Kong

Los Angeles (ANTARA News/PRNewswire-AsiaNet) - Luxe Worldwide Hotels (http://www.luxehotels.com), the leading provider of full-service representation services within the international hotel industry, proudly announces its exclusive representation of New World Hotel Management Ltd. (http://www.newworldhotels.com).

This agreement, which included a celebrated signing ceremony between the two companies in Hong Kong, furthers Luxe's presence in Asia while also strengthening its influence in China.

"This agreement immediately elevates Luxe's reputation among the most sophisticated travelers to mainland China and throughout Asia generally.

New World Hotel's selection of Luxe confirms our highly esteemed reputation and positions us for significant growth in one of the world's most dynamic economic and cultural regions.

"We look forward to many years of fruitfully partnering with this brand," said Efrem Harkham, President and CEO of Luxe.

"Luxe is an organization with the international reach and experience we respect and admire. We welcome the opportunity to work with their experienced professionals, a team that naturally complements our goals in China," stated Mr. Ray Wong, Managing Director of New World Hotel Management Ltd.

About New World Hotel Management Limited (NWHML)

New World Hotel Management Limited (NWHML) develops and manages the "New World" brand of 5-star and 4-star hotels in the major cities of Asia Pacific. NWHML also manages the Penta hotel brand at gateway cities in both China and other Asian
countries.

About Luxe Worldwide Hotels

Luxe Worldwide Hotels is a premier representation company of independently owned and operated hotels in prominent international locales.

Luxe provides global sales, reservations, marketing, and eBusiness services to hotel members throughout the world.

Make online reservations and find more Luxe Worldwide information at http://www.luxehotels.com or call toll-free +1-866-LUXE-411 within the United States and Canada 24/7.

SOURCE: Luxe Worldwide Hotels
CONTACT: Anna Gargioni of Luxe Worldwide Hotels,
+1-310-691-7716,
anna@luxehotels.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080716LAW535
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com/
Web site: http://www.luxehotels.com
http://www.newworldhotels.com/